8YY — Biolidics Income Statement
0.000.00%
Last trade - 00:00- SG$31.10m
- SG$32.56m
- SG$0.78m
Annual income statement for Biolidics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.91 | 2.31 | 2.49 | 0.277 | 0.784 |
| Cost of Revenue | |||||
| Gross Profit | 3.44 | 0.483 | 1.16 | 0.146 | 0.187 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.5 | 8.15 | 12.2 | 1.68 | 3.93 |
| Operating Profit | -4.56 | -5.83 | -9.68 | -1.4 | -3.15 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.68 | -6.04 | -9.85 | -1.51 | -3.19 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.65 | -5.98 | -9.37 | -1.51 | -3.19 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -4.65 | -5.98 | -9.37 | -2.49 | -3.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.65 | -5.98 | -9.37 | -2.49 | -3.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.018 | -0.021 | -0.024 | -0.003 | -0.003 |